Advertisement

Neuromuscular Blocking Agents

  • Rafael A. Ortega
  • Rubén Azocar

Abstract

Neuromuscular blocking agents perhaps have the most fascinating history among the drugs used in anesthesiology and intensive care. South American aborigines used curare for centuries to hunt animals before Claude Bernard showed in 1850 that these drugs act peripherally, blocking conduction where motor nerves meet the muscle (1). These historical facts should serve to remind us that this group of drugs is lethal when misused and that while paralysis occurs, intellectual function remains intact.

Keywords

Intensive Care Unit Patient Neuromuscular Blockade Neuromuscular Blocking Agent Status Asthmaticus Peripheral Nerve Stimulation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Viby-Mogensen J. Neuromuscular transmission and neuromuscular disease. In: Healey TE, Cohen PJ, eds. Wylie and Churchill-Davidson’s A Practice of Anaesthesia, 6th Ed. London. Edward Arnold, 1995: 128–46.Google Scholar
  2. 2.
    Aitkenhead AR. Awareness during anaesthesia: when is an anaesthetic not an anaesthetic? Can J Anaesth 1996; 43: 206–11.PubMedCrossRefGoogle Scholar
  3. 3.
    Johnson KL, Cheung RB, Johnson SB, Roberts M, Niblett J, Manson D. Therapeutic paralysis of critically ill trauma patients: perceptions of patients and their family members. Am J Crit Care 1999; 8: 490–8.PubMedGoogle Scholar
  4. 4.
    Sharpe MD. The use of muscle relaxants in the intensive care unit. Can J Anaesth 1992; 39: 94962.Google Scholar
  5. 5.
    Davidson JE. Neuromuscular blockade: indications, peripheral nerve stimulation, and other concurrent interventions. New Horiz 1994; 2: 75–84.PubMedGoogle Scholar
  6. 6.
    Shapiro BA, Warren J, Egol AB, Greenbaum DM, Jacobi J, Nasraway SA, Schein RM, Spevetz A, Stone JR. Practice parameters for sustained neuromuscular blockade in the adult critically ill patient: an executive summary. Society of Critical Care Medicine. Crit Care Med 1995; 23: 16015.Google Scholar
  7. 7.
    Sladen RN. Neuromuscular blocking agents in the intensive care unit: a two-edged sword. Crit Care Med 1995; 23: 423–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Sapirstein A, Hurtford WE. Neuromuscular blocking agents in the management of respiratory failure. Indications and treatment guidelines. Crit Care Clin 1994; 10: 831–43.PubMedGoogle Scholar
  9. 9.
    Murray MJ, Coursin DB, Scuderi PE, Kamath G, Prough DS, Howard DM, Abou-Donia MA. Double-blind, randomized, multicenter study of doxacurium vs. pancuronium in intensive care unit patients who require neuromuscular-blocking agents. Crit Care Med 1995; 23: 450–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Anandaciva S, Koay CW. Tetanus and rocuronium in the intensive care unit. Anaesthesia 1996; 51: 505–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Ohlinger MJ, Rhoney DH. Neuromuscular blocking agents in the neurosurgical intensive care unit. Surg Neurol 1998; 49: 217–21.PubMedCrossRefGoogle Scholar
  12. 12.
    Prielipp RC, Coursin DB. Sedative and neuromuscular blocking drug use in critically ill patients with head injuries. New Horiz 1995; 3: 456–68.PubMedGoogle Scholar
  13. 13.
    Neannan HS, Eckhauser ML. Postoperative management of a severely anemic Jehovah’s Witness. Crit Care Med 1983; 11: 142–3.CrossRefGoogle Scholar
  14. 14.
    Guyton AC. Neuromuscular transmission; function of smooth muscle. Textbook of medical physiology, 7th Ed. Philadelphia: W.B. Saunders, 1986: 136–47.Google Scholar
  15. 15.
    Reeves ST, Turcasso NM. Nondepolarizing neuromuscular blocking drugs in the intensive care unit: a clinical review. South Med J 1997; 90: 769–74.PubMedCrossRefGoogle Scholar
  16. 16.
    Stoelting RK. Neuromuscular-blocking drugs. In: Stoelting RK, ed. Pharmacology and Physiology in Anesthetic Practice, 3rd Ed. Philadelphia: Lippincott William and Wilkins, I998: 182–223.Google Scholar
  17. 17.
    Armstrong DK, Crisp CB. Pharmacoeconomic issues of sedation, analgesia and neuromuscular blockade in critical care. New Horiz 1994; 2: 85–93.PubMedGoogle Scholar
  18. 18.
    Hughes M, Grant IS, Biccard B, Nimmo G. Suxametonium and critical illness polyneuropathy. Anaesth Intensive Care 1999; 27: 636–8.PubMedGoogle Scholar
  19. 19.
    Wright PM, Brown R, Lau M, Fisher DM. A pharmacodynamic explanation for the rapid onset/offset of rapacuronium bromide. Anesthesiology I999; 90: 16–23.Google Scholar
  20. 20.
    Grigore AM, Brusco L Jr, Kuroda M, Koorn R. Laudanosine and atracurium concentrations in a patient receiving long-term atracurium infusion. Crit Care Med 1998; 26: 180–3.PubMedCrossRefGoogle Scholar
  21. 21.
    Kisor DF, Schmith VD. Clinical pharmacokinetics of cisatracurium besilate. Clin Pharmacokinet 1999; 36: 27–40.PubMedCrossRefGoogle Scholar
  22. 22.
    Newman PJ, Quinn AC, Grounds RM, Hunter JM, Boyd AH, Eastwood NB, Pollard BJ, Pearson AJ, Harper NJ, Beale RJ, Sutjarittam M, Elliot JM, Bion JF. A comparison of cisatracurium (51W89) and atracurium by infusion in critically ill patients. Crit Care Med 1997; 25: 1139–42.PubMedCrossRefGoogle Scholar
  23. 23.
    Pearson AJ, Harper NJ, Pollard BJ. The infusion requirements and recovery characteristics of cisatracurium or atracurium in intensive care patients. Intensive Care Med 1996; 22: 694–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Prielipp RC, Robinson JC, Wilson JA, MacGregor DA, Scuderi PE. Dose response, recovery, and cost of doxacurium as a continuous infusion in neurosurgical intensive care unit patients. Crit Care Med 1997; 25: 1236–41.PubMedCrossRefGoogle Scholar
  25. 25.
    Ostergaard D, Jensen FS, Jensen E, Skovgaard LT, Viby-Mogensen J. Mivacurium-induced neuromuscular blockade in patients with atypical plasma cholinesterase. Acta Anaesthesiol Scand 1993; 37: 314–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Khuenl-Brady KS, Reitstatter B, Schlager A, Schreithofer D, Luger T, Seyr M, Mutz N, Agoston S. Long-term administration of pancuronium and pipecuronium in the intensive care unit. Anesth Analg 1994; 78: 1082–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Purdy R, Bevan DR, Donati F, Lichtor JL. Early reversal of rapacuronium with neostigmine. Anesthesiology 1999; 91: 51–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Sparr HJ, Mellinghoff H, Blobner M, Noldge-Schomburg G. Comparison of intubating conditions after rapacuronium (Org 9487) and succinylcholine following rapid sequence induction in adult patients. Br J Anaesth 1999; 82: 537–41.PubMedCrossRefGoogle Scholar
  29. 29.
    Levy JH, Pitts M, Thanopoulos A, Szlam F, Bastian R, Kim J. The effects of rapacuronium on histamine release and hemodynamics in adult patients undergoing general anesthesia. Anesth Analg 1999; 89: 290–5.PubMedGoogle Scholar
  30. 30.
    Sparr HJ, Wierda JM, Proost JH, Keller C, Khuenl-Brady KS. Pharmacodynamics and phannacokinetics of rocuronium in intensive care patients Br J Anaesth 1997; 78: 267–73.Google Scholar
  31. 31.
    Prielipp RC, Coursin DB, Scuderi PE, Bowton DL, Ford SR, Cardenas VJ Jr, Vender J, Howard D, Casale EJ, Murray MJ. Comparison of the infusion requirements and recovery profiles of vecuronium and cisatracurium 51W89 in intensive care unit patients. Anesth Analg 1995; 81: 3–12.PubMedGoogle Scholar
  32. 32.
    Khuenl-Brady KS, Sparr H, Puhringer F, Agoston S. Rocuronium bromide in the ICU: dose finding and pharmacokinetics. Eur J Anaesthesiol Suppl 1995; 11: 79–80.PubMedGoogle Scholar
  33. 33.
    de Lemos JM, Carr RR, Shalansky KF, Bevan DR, Ronco J.I. Paralysis in the critically ill: intermittent bolus pancuronium compared with continuous infusion. Crit Care Med 1999; 27: 264855.Google Scholar
  34. 34.
    Light RW, Bengfort JL, George RB. The adult respiratory distress syndrome and pancuronium bromide. Anesth Ana1g 1975; 54: 219–23.Google Scholar
  35. 35.
    Murray MJ. Monitoring of peripheral nerve stimulation versus standard clinical assessment for dosing of neuromuscular blocking agents. Crit Care Med 1997; 25: 561–2.PubMedCrossRefGoogle Scholar
  36. 36.
    Segredo V, Matthay MA, Sharma ML, Gruenke LD, Caldwell JE, Miller RD. Prolonged neuromuscular blockade after long-term administration of vecuronium in two critically ill patients. Anesthesiology 1990; 72: 566–70.PubMedCrossRefGoogle Scholar
  37. 37.
    Meyer KC, Prielipp RC, Grossman JE, Coursin DB. Prolonged weakness after infusion of atracurium in two intensive care unit patients. Anesth Analg 1994; 78: 772–4.PubMedCrossRefGoogle Scholar
  38. 38.
    Prielipp RC, Coursin DB, Wood KE, Murray MJ. Complications associated with sedative and neuromuscular blocking drugs in critically ill patients. Crit Care Clin 1995; 11: 983–1003.PubMedGoogle Scholar
  39. 39.
    Klessig HT, Geiger HJ, Murray MJ, Coursin DB. A national survey on the practice patterns of anesthesiologist intensivists in the use of muscle relaxants. Crit Care Med 1992; 20: 1341–5.PubMedCrossRefGoogle Scholar
  40. 40.
    Kleinpell R, Bedrosian C, McCormick L, Kremer M., Bujalski L, Bronsted R. Use of peripheral nerve stimulators to monitor patients with neuromuscular blockade in the ICU. Am J Crit Care 1996; 5: 449–54.PubMedGoogle Scholar
  41. 41.
    Rudis MI, Guslits BJ, Peterson EL, Hathaway SJ, Angus E, Beis S, Zarowitz BJ. Economic impact of prolonged motor weakness complicating neuromuscular blockade in the intensive care unit. Crit Care Med 1996; 24: 1749–56.PubMedCrossRefGoogle Scholar
  42. 42.
    Frankel H, Jeng J, Tilly E, St Andre A, Champion H. The impact of implementation of neuromuscular blockade monitoring standards in a surgical intensive care unit. Am Surg 1996; 62: 503–6.Google Scholar
  43. 43.
    Rudis MI, Sikora CA, Angus E, Peterson E, Popovich J Jr, Hyzy R, Zarowitz BJ. A prospective, randomized, controlled evaluation of peripheral nerve stimulation versus standard clinical dosing of neuromuscular blocking agents in critically ill patients. Crit Care Med 1997; 25: 57583.CrossRefGoogle Scholar
  44. 44.
    Donati F, Antzaka C, Bevan DR. Potency of pancuronium at the diaphragm and the adductor pollicis muscle in humans. Anesthesiology 1986; 65: 1–5.PubMedCrossRefGoogle Scholar
  45. 45.
    Donati F, Meistelman C, Plaud B. Vecuronium neuromuscular blockade at the diaphragm, the orbicularis oculi, and adductor pollicis muscles. Anesthesiology 1990; 73: 870–5.PubMedCrossRefGoogle Scholar
  46. 46.
    de Rossi L, Fritz H, Krober L, Klein U. Cisatricurium in the orbicularis oculi muscle. Comparison of the neuromuscular action of cisatracurium and atracurium in the orbicularis oculi muscle and the adductor pollicis muscle. Anaesthetist 1999; 48: 602–6.Google Scholar
  47. 47.
    Rudis MI, Guslits BG, Zarowitz BJ. Technical and interpretive problems of peripheral nerve stimulation in monitoring neuromuscular blockade in the intensive care unit. Ann Pharmacother 1996; 30: 165–72.PubMedGoogle Scholar
  48. 48.
    Segredo V, Caldwell JE, Matthay MA, Sharma ML, Gruenke LD, Miller RD. Persistent paralysis in critically ill patients after long-term administration of vecuronium. N Engl J Med 1992; 327: 524–8.PubMedCrossRefGoogle Scholar
  49. 49.
    Watling SM, Dasta JF. Prolonged paralysis in intensive care unit patients after the use of neuromuscular blocking agents: a review of the literature. Crit Care Med 1994; 22: 884–93.PubMedCrossRefGoogle Scholar
  50. 50.
    Hoyt JW. Persistent paralysis in critically ill patients after the use of neuromuscular blocking agents. New Horiz 1994; 2: 48–55.PubMedGoogle Scholar
  51. 51.
    Prielipp R, Jackson MJ, Coursin D. Comparison of neuromuscular recovery after paralysis with atracurium versus vecuronium in an ICU patient with renal insufficiency. Anesth Analg 1994; 78: 775–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Sokoll MD, Gergis SD. Antibiotics and neuromuscular function. Anesthesiology 1981; 55: 148–59.PubMedCrossRefGoogle Scholar
  53. 53.
    Fuchs-Buder T, Suter PM. Recovery properties of cisatracurium and vecuronium in intensive care unit patients. Anesth Analg 1996; 82: 892–3.PubMedGoogle Scholar
  54. 54.
    Erkola O. Complications of neuromuscular blockers: Interaction with concurrent medications and other neuromuscular blockers. Anesthesiol Clin North Am 1993; 11: 427–42.Google Scholar
  55. 55.
    Lewis KS, Rothenberg DM. Neuromuscular blockade in the intensive care unit. Am J Health Syst Pharm 1999; 56: 72–5.PubMedGoogle Scholar
  56. 56.
    Hund E. Myopathy in critically ill patients. Crit Care Med 1999; 27: 2544–7.PubMedCrossRefGoogle Scholar
  57. 57.
    Hirano M, Ott BR, Raps EC, Minetti C, Lennihan L, Libbey NP, Bonilla E, Hays AR Acute quadriplegic myopathy: a complication of treatment with steroids, nondepolarizing blocking agents, or both. Neurology 1992; 42: 2082–7.PubMedCrossRefGoogle Scholar
  58. 58.
    Fischer JR, Baer RK. Acute myopathy associated with combined use of corticosteroids and neuromuscular blocking agents. Ann Pharmacother 1996; 30: 1437–45.PubMedGoogle Scholar
  59. 59.
    David WS, Roehr CL, Leatherman JW. EMG findings in acute myopathy with status asthmaticus, steroids and paralytics. Clinical and electrophysiologic correlation. Electromyogr Clin Neurophysiol 1998; 38371–6.Google Scholar
  60. 60.
    Lacomis D, Giuliani MJ, Van Cott A, Kramer DJ. Acute myopathy of intensive care: clinical, electromyographic, and pathological aspects. Ann Neurol 1996; 40: 645–54.PubMedCrossRefGoogle Scholar
  61. 61.
    Zochodne DW, Ramsay DA, Saly V, Shelley S, Moffatt S. Acute necrotizing myopathy of intensive care: electrophysiological studies. Muscle Nerve 1994; 17: 285–92.PubMedCrossRefGoogle Scholar
  62. 62.
    Helliwell TR, Coakley JH, Wagenmakers AJ, Griffiths RD, Campbell IT, Green CJ, McClelland P, Bone JM. Necrotizing myopathy in critically-ill patients. J Pathol 1991; 164: 307–14.PubMedCrossRefGoogle Scholar
  63. 63.
    Larsson L, Li X, Edstrom L, Eriksson LI, Zackrisson H, Argentini C, Schiaffinio S. Acute quadriplegia and loss of muscle myosin in patients treated with nondepolarazing neuromuscular blocking agents and corticosteroids: mechanisms at the cellular and molecular levels. Crit Care Med 2000; 28: 34–45.PubMedCrossRefGoogle Scholar
  64. 64.
    Griffm D, Fairman N, Coursin D, Rawsthorne L, Grossman JE. Acute myopathy during treatment of status asthmaticus with corticosteroids and steroidal muscle relaxants. Chest 1992; 102: 510–4.CrossRefGoogle Scholar
  65. 65.
    Lacomis D, Smith TW, Chad DA. Acute myopathy and neuropathy in status asthmaticus: case report and literature review. Muscle Nerve 1993; 16: 84–90.PubMedCrossRefGoogle Scholar
  66. 66.
    Behbehani NA, Al-Mane F, D’yachkova Y, Pare P, FitzGerald JM. Myopathy following mechanical ventilation for acute severe asthma: the role of muscle relaxants and corticosteroids. Chest 1999; 115: 1627–31.PubMedCrossRefGoogle Scholar
  67. 67.
    Rouleau G, Karpati G, Carpenter S, Soza M, Prescott S, Holland P. Glucocorticoid excess induces preferential depletion of myosin in denervated skeletal muscle fibers. Muscle Nerve 1987; 10: 428–38.PubMedCrossRefGoogle Scholar
  68. 68.
    Tousignant CP, Bevan DR, Eisen AA, Fenwick JC, Tweedale MG. Acute quadriparesis in an asthmatic treated with atracurium. Can J Anaesth 1995; 42: 224–7.PubMedCrossRefGoogle Scholar
  69. 69.
    Davis NA, Rodgers JE, Gonzalez ER, Fowler AA 3rd. Prolonged weakness after cisatracurium infusion: a case report. Crit Care Med 1998; 26: 1290–2.PubMedCrossRefGoogle Scholar
  70. 70.
    Hoke A, Rewcastle NB, Zochodne DW. Acute quadriplegic myopathy unrelated to steroids or paralyzing agents: quantitative EMG studies. Can J Neurol Sci 1999; 26: 325–9.PubMedGoogle Scholar
  71. 71.
    Miro O, Salmeron JM, Masanes F, Alonso JR, Graus F, Mas A, Grau JM. Acute quadriplegic myopathy with myosin-deficient muscle fibres after liver transplantation: defining the clinical picture and delimiting the risk factors. Transplantation 1999; 67: 1144–51.PubMedCrossRefGoogle Scholar
  72. 72.
    Stoeling RK. Anticholinesterase drugs and cholinergic agonists. In: Stoeling RK, ed. Pharmacology and Physiology in Anesthetic Practice. 3rd Ed. Philadelphia: Lippincott-Raven Publishers, 1999: 224–37.Google Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Rafael A. Ortega
    • 1
  • Rubén Azocar
    • 1
  1. 1.Boston University Medical CenterBostonUSA

Personalised recommendations